Objective: Current guidelines recommend a serum potassium (sK) level of 4.0-5.0 mmol/L in acute myocardial infarction patients. Recent trials have demonstrated an increased mortality rate with an sK level of >4.5 mmol/L. The aim of this study was to figure out the relation between admission sK level and in-hospital and long-term mortality and ventricular arrhythmias.

Methods: Retrospectively, 611 patients with ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention were recruited. Admission sK levels were categorized accordingly: <3.5, 3.5-<4, 4-<4.5, 4.5-<5, and ≥5 mmol/L.

Results: The lowest in-hospital and long-term mortality occurred in patients with sK levels of 3.5 to <4 mmol/L. The long-term mortality risk increased for admission sK levels of >4.5 mmol/L [odds ratio (OR), 1.58; 95% confidence interval (CI) 0.42–5.9 and OR, 2.27; 95% CI 0.44–11.5 for sK levels of 4.5-<5 mmol/L and ≥5 mmol/L, respectively]. At sK levels <3 mmol/L and ≥5 mmol/L, the incidence of ventricular arrhythmias was higher (p=0.019).

Conclusion: Admission sK level of >4.5 mmol/L was associated with increased long-term mortality in STEMI. A significant relation was found between sK level of <3 mmol/L and ≥5 mmol/L and ventricular arrhythmias. (Anatol J Cardiol 2016; 16: 10-5)

Keywords: potassium, mortality, myocardial infarction, ventricular arrhythmia, hypokalemia

Introduction

Serum K (sK) level is critical in cardiovascular diseases for the prevention of adverse events. Most of the body K is intracellularly located (98%), and a level of 3.5-5.3 mmol/L is maintained by intra and extracellular shifts and renal excretion (1). Hypokalemia is defined as sK levels of <3.5 mmol/L and plays an important role in cardiovascular disease pathogenesis (2). Studies showed that at the acute phase of myocardial infarction (MI), hypokalemia occurs that as a consequence could lead to ventricular arrhythmia (3-7). Potassium mediates vasodilatation by Na-K-ATPase pump and inwardly rectifying K channels (8). Also, K inhibits vasoconstriction associated with angiotensin-II (9). As a consequence, a low level of K further enhances infarction and ischemia. Previous studies showed that hypokalemia is a fairly common finding on admission in acute MI patients (5, 9-11). The mean admission level of sK was approximately 4 mmol/L (9, 10). This level is not defined as hypokalemia. It was reported that after ischemic attack, during the stable phase, the sK level significantly increases with a mean value of 4.4 mmol/L (10).

The current guidelines recommend maintaining an sK level of >4-4.5 mmol/L in MI patients (1, 11). On the other hand, very recent clinical trials presented increased mortality with sK level of >4.5 mmol/L (12, 13). The objective of the present study is to figure out the relation between admission sK level and in-hospital mortality, ventricular arrhythmias, long-term (six months) mortality, and hospitalization in acute ST-elevation myocardial infarction (STEMI) patients who underwent primary PCI.

Methods

Patients

The present study was a retrospective observational study. A total of 611 patients who fulfilled the criteria were recruited in the study. The study was conducted from October 2011 to December 2012 in a single center. Patients presenting within 12
h of typical chest pain lasting for >30 min and diagnosed with STEMI and treated with primary PCI (angioplasty and/or stent deployment) were enrolled for the study. The specific electrocardiographic criteria advised by the European Society Cardiology/American College of Cardiology Foundation/ American Heart Association committee were used for the diagnosis of STEMI (14). These were new ST segment elevation of >0.1 mV in two contiguous leads or those with a true posterior MI or those with definite or probably a new left bundle branch block. Patients treated with coronary artery bypass grafting or who were treated medically or receiving dialysis or who have no follow-up data upon discharge the hospital (patients who were not contacted either by phone or who did not re-admit to hospita- tal) were excluded. The study was undertaken in a high volume tertiary center none? (>3000 PCI/year). The primary PCI procedures were performed by an expert interventional cardiologist who performed >75 PCI/year.

The primary end points were in-hospital and six month mor- tality and ventricular arrhythmias, and the secondary end point was hospitalization.

The Local Ethics Committee of the hospital with 2013/KK/98 number approved the study protocol.

Data sources

The baseline demographic data was retrospectively collected from medical records. Laboratory parameters for each patient were determined at hospital admission and on a daily basis during the hospital stay. Serum K level was measured by the ISE indirect method using Rosch, Cobas 6000 Biochemistry Auto-Analyzer, USA. The admission sK level was categorized accordingly: <3.5, 3.5-<4, 4-<4.5, 4.5-<5 and ≥5 mmol/L. The estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft–Gault equation (15). The left ventricular ejection fraction (EF) was measured using a modified Simpson’s rule on the day of hospitaliza- tion at the coronary care unit following primary PCI (16). Follow-up data were obtained from hospital records or by interviewing the patients (directly or by telephone) or their families.

Coronary angiography, medication

Angiographic data of the patients were obtained from the cardiac catheterization laboratory records. Emergency coronary angiography was performed by the percutaneous femoral approach. In all cases, non-ionic low-osmolality contrast media was used. Thrombolysis in myocardial infarction score was used for PCI success. Following angioplasty, patients were admitted to the coronary care unit. The drugs were adminis- tered during and after the PCI procedure according to the European Society of Cardiology PCI Guidelines (17).

Statistical analysis

Group significance analysis of continuous variables with normal distributions was compared using one-way analysis of variance. The Kruskal-Wallis test was used to compare continuous variables with a skewed distribution. All continuous variables are expressed as mean±SD (standard deviation). Pearson’s chi-square or Fisher’s exact test were used to evaluate the differences in categorical variables, which were expressed as numbers and percentages. The Kolmogorov-Smirnov test was used for testing normality.

Demographics and clinical characteristics were compared among the patients categorized by the following mean admission sK levels (mmol/L): <3.5, 3.5-<4, 4-<4.5, 4.5-<5, and ≥5. Hierarchical logistic regression was then used to evaluate the independent association between mean admission sK levels and mortality after adjustments for the confounders. The confounders analyzed included age, gender, eGFR, Killip class, left ventricular EF, past history (hypertension, diabetes mellitus, coronary artery disease, hyperlipidemia, and smoking status), diagnosis (anterior STEMI), cardiac enzymes (peak CK-MB lev- els during hospitalization), and medication before hospitaliza- tion. The most comprehensive logistic model was generated by the stepwise model analyze. The group of 3.5-<4 was used as the reference group in multivariate logistic analyze. A two-sided p value of <0.05 was considered to be statistically significant, and 95% CIs were presented for all odds ratios (ORs). Analyses were conducted with the Statistical Package for Social Sciences soft- ware, version 14.0 (SPSS; IBM, Armonk, New York, USA).

Results

A total of 611 patients (mean age 59±13.6 years; male 86%) were included in the present study. There were significant dif- ferences in terms of gender (p=0.006) and age (p=0.001) among the subgroups of K level. However, there was no difference in terms of body mass index (kg/m²). There were complex differences in clinical characteristics among the groups. The history of patients showed diversity only with diabetes mellitus (p=0.032) and hypertension (p=0.024). There was significant difference in terms of Killip Class (p=0.001), anterior STEMI (p=0.009), and heart rate (p=0.003) at admission among the groups of sK levels. With regard to clinical outcomes, the lowest in-hospital and long-term mortality occurred in patients with K levels of 3.5-<4 mmol/L. Moreover, the highest in-hospital mortality (16%) was seen in the group of patients with sK ≥5 (p=0.002). Similarly, long- term (six months) mortality was positively correlated by increasing sK levels as well (p=0.007). Ventricular tachycardia/ventricu- lar fibrillation (VT/VF) was different in that its frequency increased by not only increasing sK level but also decreasing sK level (p=0.019). The patients’ clinical characteristics stratified by mean sK level are listed in Table 1.

The unadjusted and adjusted models of logistic regression analysis for mortality according to sK levels are listed in Table 2. The mortality had the highest rates at sK levels of ≥5 mmol/L and that had 12.2-times higher mortality rates (95% CI: 2.5-58.5) than sK levels of 3.5-<4 mmol/L, which had the lowest rates and which was used as the reference. Compared with the reference group (3.5-<4.0 mmol/L), the long-term mortality risk was 9.55-times
Table 1. Baseline characteristics of patients by admission serum potassium levels

| Serum potassium (mmol/L) (Mean) | <3.5 | 3.5–<4 | 4–<4.5 | 4.5–<5 | ≥5 | P |
|---------------------------------|------|--------|--------|--------|----|---|
| Patients, n                     | 41   | 196    | 241    | 108    | 25 |   |
| Age*, years                     | 62±11| 55±12  | 56±12  | 58±11  | 63±15| 0.001|
| Gender, Female                  | 14 (34.1) | 23 (11.7) | 26 (10.8) | 15 (13.9) | 6 (24.0) | 0.006|
| BMI, kg/m²*                     | 27.6±4.1 | 27.3±3.8 | 27.7±4 | 27.7±5.5 | 27±5 | 0.817|
| Serum K, mEq/L                  | 3.2±0.2 | 3.8±0.1 | 4.2±0.1 | 4.7±0.1 | 5.2±0.2 | 0.001|

**Patient’s history**

| Smoking, n (%)                  | 24 (58.5) | 151 (77) | 178 (73.9) | 83 (76.9) | 19 (76) | 0.162|
| Diabetes, n (%)                 | 8 (19.5) | 23 (11.7) | 55 (22.8) | 25 (23.1) | 6 (24) | 0.032|
| Hypertension, n (%)             | 25 (61) | 70 (35.7) | 99 (41.1) | 36 (33.3) | 11 (44) | 0.024|
| Hyperlipidemia, n (%)           | 15 (36.6) | 40 (20.4) | 60 (24.9) | 22 (20.4) | 6 (24) | 0.213|
| CAD, n (%)                      | 7 (17.1) | 24 (12.2) | 34 (14.1) | 15 (13.9) | 2 (8) | 0.835|

**Previous medication**

| Beta-blocker, n (%)             | 5 (12.2) | 25 (12.8) | 30 (12.4) | 14 (13) | 4 (16) | 0.992|
| ACE/ARB, n (%)                  | 15 (36.6) | 41 (20.9) | 57 (23.7) | 25 (23.1) | 6 (25) | 0.325|
| Diuretics, n (%)                | 2 (4.9) | 1 (0.5) | 6 (2.5) | 3 (2.8) | 0 (0) | 0.27|
| ASA, n (%)                      | 8 (19.5) | 24 (12.2) | 42 (17.4) | 18 (16.7) | 4 (16) | 0.585|
| CCB, n (%)                      | 6 (14.6) | 5 (2.6) | 12 (5) | 4 (3.7) | 1 (4) | 0.2|
| Statin, n (%)                   | 5 (12.2) | 13 (6.6) | 24 (10) | 4 (3.7) | 2 (8.3) | 0.245|
| OAD, n (%)                      | 5 (12.2) | 12 (6.1) | 28 (11.6) | 14 (13) | 4 (16) | 0.198|
| Insulin, n (%)                  | 2 (4.9) | 4 (2) | 13 (5.4) | 4 (3.7) | 1 (4) | 0.503|

**Laboratory parameters**

| Hemoglobin, mg/dL *             | 13.3±1.5 | 14±1.6 | 14.1±1.6 | 14.4±3 | 13.8±2 | 0.180|
| WBC, 10³/µL                     | 11.1±3.3 | 12.3±3.4 | 13±1.5 | 12.9±7.9 | 13.9±5.6 | 0.225|
| LDL, mg/dL*                     | 112±39 | 121±36 | 121±31 | 121±37 | 111±43 | 0.496|
| HDL, mg/dL*                     | 39±11.4 | 39±9.6 | 39±11.8 | 38±10.6 | 39±12.3 | 0.955|
| CK-MB, u/L                      | 217±162 | 162±142 | 186±150 | 181±195 | 216±147 | 0.051|
| Admission glucose, mg/dL        | 157±51 | 150±54 | 161±76 | 161±74 | 176±100 | 0.695|
| HbA1c, %                        | 6±0.9 | 6±1 | 6±1.6 | 6±1.4 | 6.5±1.2 | 0.016|
| Creatinine, mg/dL               | 0.8±0.3 | 0.8±0.2 | 0.9±0.3 | 1±0.3 | 1.3±0.7 | 0.001|
| GFR C-G, mL/min/1.73 m²         | 104±43 | 120±45 | 115±49 | 103±46 | 76±40 | 0.001|

**At admission**

| Killip class                    | 1±0.2 | 1.1±0.4 | 1.2±0.6 | 1.2±0.7 | 1.8±1.2 | 0.001|
| Ejection fraction, %            | 44.9±6.9 | 46.3±8.1 | 44.8±9 | 45.5±8.8 | 42.2±10.5 | 0.199|
| Anterior MI, n (%)              | 19 (46.3) | 81 (41.3) | 136 (56.4) | 43 (39.8) | 11 (44) | 0.009|
| SBP, mm Hg                      | 123±19 | 123±22 | 123±23 | 126±28 | 126±42 | 0.398|
| DBP, mm Hg                      | 71±10 | 71±14 | 71±54 | 74±19 | 74±22 | 0.101|
| HR, /min                        | 77±11 | 77±11 | 77±14 | 80±13 | 80±17 | 0.003|

**Clinical outcomes**

| Mortality, n (%) (in-hospital)  | 1 (2.4) | 3 (1.5) | 8 (3.3) | 2 (1.9) | 4 (16) | 0.002|
| Mortality, n (%) (sixth months) | 2 (4.9) | 5 (2.6) | 13 (5.4) | 7 (6.5) | 5 (20) | 0.007|
| VT-VF, n (%)                    | 7 (17.1) | 15 (7.7) | 26 (10.8) | 10 (9.3) | 7 (28) | 0.019|
| Hospitalization, n (%) (day)    | 7.3±4.1 | 6.9±6 | 7.9±7.8 | 8.1±5.9 | 11.2±18.6 | 0.092|

ACE - angiotensin-converting enzyme; ARB - angiotensin II receptor blocker; ASA - acetylsalicylic acid; BMI - body mass index; CAD - coronary artery disease; CCB - calcium channel blocker; CK-MB - creatinine kinase-myocardial band; DBP - diastolic blood pressure; GFR C-G - glomerular filtration rate; Cockcroft-Gault; HDL - high density lipoprotein; HR - heart rate; LDL - low density lipoprotein; MI - myocardial infarction; OAD - oral anti-diabetic; SBP - systolic blood pressure; VT-VF - ventricular tachycardia-ventricular fibrillation; WBC - white blood cell.

Continuous variables are reported as mean±SD; Nominal variables as frequency (%) unless otherwise indicated.

*ANOVA significance test is used for the parameters with normal distribution.
higher for admission sK levels of ≥5 mmol/L (95% CI: 2.54-35.8).

Ventricular arrhythmias were noted in 65 (10%) patients during hospitalization. The lowest incidence of ventricular arrhythmias was noted in sK levels of 3.5-<4 mmol/L (reference group). The incidence of ventricular arrhythmias was higher at sK levels <3 mmol/L and ≥5 mmol/L. Logistic regression analysis showed a significant increase in the risk of ventricular arrhythmias at sK levels of <3 mmol/L (OR, 2.48; 95% CI: 0.94-6.5) and ≥5 mmol/L (OR, 4.69, 95% CI: 1.69-13) (Table 2). All ORs were regressed by extended models (from Model 1 to Model 4) for in-hospital mortality, VT-VF, and long-term mortality. The CIs in Table 2 were wide. We thought that this could probably be because of low sample volume.

Figure 1 shows the distribution of admission sK levels. The median admission sK level was 4 mmol/L with intervals as 2.4-5.6 mmol/L. Figure 2 demonstrates the relation of admission sK level groups with the in-hospital and long-term mortality and ventricular arrhythmias. A U-shaped relation was observed between admission sK level and in-hospital and long-term mortality and ventricular arrhythmias.

Discussion

The results of the present study revealed that admission sK level of ≥4.5 mmol/L was associated with increased long-term mortality in patients with STEMI treated with primary PCI. A significant relation was detected between admission sK level of
<3 mmol/L and ≥5 mmol/L and ventricular arrhythmia. An sK level of 3.5-4 mmol/L was found to be associated with the lowest mortality. Acute MI is accompanied by a catecholamine surge (3). Catecholamine by stimulating Na-K-ATPase pump shifts K intra-
cellularly, thus causing redistributional hypokalemia, and as a result, non-ischemic myocardium is hyperpolarized. As a conse-
quence, electrical inhomogeneity occurs and leads to ventricu-
lar arrhythmia (3, 4). Most prior studies had proposed an increased rate of ventricular arrhythmia during the acute course of MI that was found to be associated with hypokalemia (7, 18-20). Most of these studies were conducted prior to modern treatment modalities such as beta-blocker and early reperfusion treatment. Based on these previous studies, guidelines recom-
manded a serum level of >4-4.5 mmol/L in acute MI (1, 11). Beta-
blockers increase sK level and inhibit ventricular arrhythmias by blocking catecholamine-induced depression of K level that is derived by the inhibition of Na-K-ATPase pump by beta-2 receptors (6, 21-22). In a recent study, it was shown that the early administra-
tion of beta-blockers is associated with decreased incidence of ventricular arrhythmias in STEMI (23). Additionally, beta-blockers decrease sudden cardiac death and mortality after MI (24, 25). In the present study, there was a significant difference at the extremes of sK levels. This finding is similar to the study by Goyal et al. (12) but is different from that by Choi et al. (13). In our center, all patients following the emergent PCI were administered evidence-based treatment including appropriate beta-blocker drugs.

A high volume study performed by Goyal et al. (12) interest-
ingly revealed that mean sK level above 4.5 mmol/L is associated with increased mortality. They suggested that K level between 3.5 and 4.5 mmol/L is the optimal range for acute MI patients (12). This finding was a challenge against the guidelines’ recommenda-
tion for sK level. A very recent study conducted by Choi et al. (13) supported Goyal et al’s (12) finding. They demonstrated that mean sK level of >4.5 mmol/L is associated with increase in hospital and long-term mortality (13). Even though in that study, the K level of >4.5 mmol/L group was less frequently treated with beta-blockers and angiotensin-converting enzyme inhibitors, after the adjustment of confounders, the mean sK level of >4.5 mmol/L was associated with increased long-term mortality (13). Although the present study evaluated the admission sK level rather than the mean sK level, our results showed similarity with both studies (12, 13). We found that long-term mortality increased in sK level of >4.5 mmol/L.

The present study also showed that as the sK level increased, the KILLIP class also increased, and at the highest sK level, EF was the lowest. This finding was supported by Choi et al. (13). This could be partially explained by the effect of hypokalemia impairing the contractility and relaxation of myocardium because of the high levels of vasopressors (26, 27).

At the acute phase of MI, some kind of insulin resistance is seen (28, 29). It has been shown that a higher level of admission serum glucose level is seen during the acute phase of MI and that this is associated with increased in-hospital and long term mortality (28, 29). In this regard, the present study showed a positive correlation between admission sK level and admission glucose and HgA1c levels.

Serum K level is maintained by intra and extracellular shifts and renal excretion (1). As eGFR decreases, sK level increases. eGFR is an independent predictor of mortality and complications after MI (30). In the present study, a similar finding was detect-
ed. Admission sK level is positively correlated with admission creatinine level and is negatively correlated with eGFR.

**Study limitations**

The present study had some limitations. This was a single-
center, retrospective, observational study. Post discharge sK levels were not recorded; thus the effect of post-discharge K level on clinical outcomes could not be determined. The effect of medication on sK level and thus the outcomes were not evaluated. Hormonal changes such as serum catecholamine, insulin, and cortisol were not evaluated. Thus, the exact relation of sK level with hormonal changes was not assessed. The time of ventricular arrhythmias was not noted.

**Conclusion**

It can be concluded that admission sK level was signifi-
cantly associated with in-hospital and long-term mortality in STEMI. An sK level of >4.5 mmol/L was associated with increased long-term mortality. Ventricular arrhythmia risk was increased at extreme levels of sK. In association with recent studies, we thought that the ideal sK level could be different from that that has been proposed. To address this issue, randomized controlled trials should be undertaken.

**Conflict of interest:** None declared.

**Peer-review:** Externally peer-reviewed.

**Authorship contributions:** Concept - M.U., A.E.; Design - M.U.; Supervision - H.U., M.E.; Resource - A.M., Ş.A., G.Ç.; Materials - M.B.; Data collection &/or processing - M.B., G.Ç., A.M.; Analysis &/or interpre-
tation - M.U., T.K.U., G.K.; Literature search - M.U., Ş.A.; Writing - M.U., T.K.U.; Critical review - H.U., M.E., A.E.

**References**

1. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004; 43: 155-61.
2. Schulman M, Narins RG. Hypokalemia and cardiovascular disease. Am J Cardiol 1990; 65: 4-9.
3. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2 receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309: 1414-9.
4. Obeid AI, Verrier RL, Lown B. Influence of glucose, insulin, and potassium on vulnerability to ventricular fibrillation in the canine heart. Circ Res 1978; 43: 601-8.
5. Madias NE, Shah B, Chintalapally G, Chalavarya G, Madias NE. Admission serum potassium in patients with acute myocardial infarction: its correlates and value as a determinant of in-hospital outcome. Chest 2000; 118: 904-13.

6. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation 1985; 71: 645-9.

7. Friedensohn A, Faibel HE, Bairey O, Goldbourt U, Schlesinger Z. Malignant arrhythmias in relation to values of serum potassium in patients with acute myocardial infarction. Int J Cardiol 1991; 32: 331-8.

8. Dawes M, Sieniawska C, Delves T, Dwivedi R, Chowienczyk PJ, Ritter JM. Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm. Circulation 2002; 105: 1323-8.

9. Campbell WB, Schmitz JM. Effect of alterations in dietary potassium on the pressor and steroidogenic effects of angiotensins II and III. Endocrinology 1978; 103: 2098-104.

10. Sekiyama H, Nagoshi T, Komukai K, Matsushima M, Katoh D, Ogawa K, et al. Transient decrease in serum potassium level during ischemic attack of acute coronary syndrome: paradoxical contribution of plasma glucose level and glycohemoglobin. Cardiovasc Diabetol 2013; 12: 4.

11. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000; 160: 2429-36.

12. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307: 157-64.

13. Choi JS, Kim YA, Kim HY, Oak CY, Kang YU, Kim CS, et al. Relation of serum potassium level to long-term outcomes in patients with acute myocardial infarction. Am J Cardiol 2014; 113: 1285-90.

14. Thygensen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-95.

15. Cockcroft D. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.

17. Wiens W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardiothoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-55.

18. Herlitz J, Hjalmarson A, Bengtson A. Occurrence of hypokalemia in suspected acute myocardial infarction and its relation to clinical history and clinical course. Clin Cardiol 1988; 11: 678-82.

19. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. Acta Med Scand Suppl 1981; 647: 109-16.

20. Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 1987; 147: 465-9.

21. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309: 1414-9.

22. Johansson BW, Dziamski R. Malignant arrhythmias in acute myocardial infarction: relationship to serum potassium and effect of selective and nonselective beta-blockade. Drugs 1984; 28: 77-85.

23. Park KL, Goldberg RJ, Anderson FA, López-Sendón J, Montalescot G, Brieger D, et al. GRACE Investigators. Beta-blocker Use in ST-segment Elevation Myocardial Infarction in the Reperfusion Era (GRACE). Am J Med 2014; 127: 503-11.

24. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfection in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.

25. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I, mortality results. JAMA 1982; 247: 1707-14.

26. Fitzgivich DE, Hamaguchi M, Tull WB, Young DB. Chronic hypokalemia and the left ventricular responses to epinephrine and preload. J Am Coll Cardiol 1991; 18: 1105-11.

27. Shapero JL, Banerjee A, Reiss OK, Elkins N. Acute and chronic hypokalemia sensitize the isolated heart to hypoxic injury. Am J Physiol 1998; 274: H1598-H1604.

28. Ekmeckci A, Uluganyan M, Tufan F, Uyarel H, Karaca G, Kul S, et al. Impact of admission blood glucose levels on prognosis of elderly patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. J Geriatr Cardiol 2013; 10: 310-6.

29. Ekmecki A, Çiçek G, Uluganyan M, Güngor B, Osman F, Özcan KS, et al. Admission hyperglycemia predicts in-hospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. Angiology 2014; 65: 154-9.

30. Bae EH, Lim SY, Cho KH, Choi JS, Kim CS, Park JW, et al. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. Am J Kidney Dis 2012; 59: 795-802.